Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and other dimethoxyphenyl-N-[(2-methoxyphenyl) methyl]ethanamine derivatives on blotter paper

Journal of Analytical Toxicology

Volumn 39, Issue 8, 2015, Pages 617-623

  Poklis, Justin L ^a   Raso, Stephen A ^a   Alford, Kylie N ^a   Poklis, Alphonse ^a   Peace, Michelle R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,5 DIMETHOXY 4 (METHYLTHIO)PHENYL) N (2 METHOXYBENZYL)ETHANAMINE; 2 (2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYLIDENE) ETHANAMINE; 2 (2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYLIDENE)ETHANAMINE; 2 (4 IODO 2,5 DIMETHOXYPHENYL) N (2 METHOXYBENZYLIDENE)ETHANAMINE; DIMETHOXYPHENYL N [(2 METHOXYPHENYL) METHYL]ETHANAMINE; ETHYLAMINE; METHANOL; N (2 FLUOROBENZYL) 2 (4 IODO 2,5 DIMETHOXYPHENYL)ETHANAMINE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 BROMOPHENETHYLAMINE; N (2 METHOXYBENZYL) 2,5 DIMETHOXY 4 CHLOROPHENETHYLAMINE; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG; 2-(4-BROMO-2,5-DIMETHOXYPHENYL)-N-((2-METHOXYPHENYL)METHYL)ETHANAMINE; 2-(4-CHLORO-2,5-DIMETHOXYPHENYL)-N-((2-METHOXYPHENYL)METHYL)ETHANAMINE; 2-(4-IODO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL)ETHANAMINE; ANISOLE DERIVATIVE; BENZYLAMINE DERIVATIVE; HOMOVERATRYLAMINE; PHENETHYLAMINE DERIVATIVE;

ARTICLE; BLOTTER PAPER; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; ELECTRIC POTENTIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELTING POINT; PAPER; QUALITY CONTROL; SEPARATION TECHNIQUE; SIGNAL NOISE RATIO; ANALOGS AND DERIVATIVES; TANDEM MASS SPECTROMETRY;

ANISOLES; BENZYLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMETHOXYPHENYLETHYLAMINE; PHENETHYLAMINES; TANDEM MASS SPECTROMETRY;

EID: 84943794824     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkv073     Document Type: Article

References (30)

1. Dean, B.V., Stellpflug, S.J., Burnett, S.M., Engebretsen, K.M. (2013) 2C or not 2C: Phenethylamine designer drug review. Journal of Medical Toxicology, 9, 172.
2. González-Maeso, J.,Weisstaub, N.V., Zhou, M., Chan, P., Ivic, L., Ang, R. et al. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron, 53, 439-452.
3. Shulgin, A.T., Carter, M.F. (1975) Centrally active phenethylamines. Psychopharmacol Commun, 1, 93-98.
4. Shulgin, A., Shulgin, A. (1991) PIHKAL: A Chemical Love Story. Transform Press, Berkeley, CA.
5. Heim, R., Pertz, H.H., Elz, S. (2000) Partial 5-HT2A-receptor agonists of the phenylethanamine series: effect of a trifluoromethyl substituent. Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry, 333, 45.
6. Pertz, H.H., Heim, R., Elz, S. (2000) N-Benzylated phenylethanamines are highly potent partial agonists at 5-HT2A receptors. Archiv der Pharmazie - Pharmaceutical and Medicinal Chemistry, 333, 30.
7. Heim, R. (2013) Synthese und pharmakologie potenter 5-HT2Arezeptoragonisten mit N-2-methoxybenzyl-partialstruktur. Entwicklung eines neuen struktur-wirkungskonzepts. Free University of Berlin, Berlin.
8. Stellpflug, S.J., Kealey, S.E., Hegarty, C.B., Janis, G.C. (2014) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. Journal of Medical Toxicology, 10, 45-50.
9. Zuba, D., Sekuła, K. (2013) Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis, 8, 634-645.
10. Zuba, D., Sekula, K., Buczek, A. (2013) 25C-NBOMe - new potent hallucinogenic substance identified on the drug market. Forensic Science International, 227, 7-14.
11. Sekuła, K., Zuba, D. (2013) Structural elucidation and identification of a new derivative of phenethylamine using quadrupole timeof-flight mass spectrometry. Rapid Communications in Mass Spectrometry, 18, 2081-2090.
12. Kelly, A., Eisenga, B., Riley, B., Judge, B. (2012) Case series of 25I-NBOMe exposures with laboratory confirmation. Clinical Toxicology (Philadelphia), 50, 702.
13. Rose, S.R., Cumpston, K.L., Stromberg, P.E., Wills, B.K. (2012) Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Clinical Toxicology (Philadelphia), 50, 707-708.
14. Rose, R.S., Poklis, J.L., Poklis, A. (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5HT2a agonist designer drug. Clinical Toxicology (Philadelphia), 51, 174-177.
15. Hill, S.L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M. et al. (2013) Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clinical Toxicology (Philadelphia), 51, 487-492.
16. Suzuki, J., Poklis, J.L., Poklis, A. (2014) "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion. Journal of Psychoactive Drugs, 46, 379-382.
17. Poklis, J.L., Nanco, C.R., Troendle, M.M., Wolf, C.E., Poklis, A. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)-methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Testing and Analysis, 6, 764-769.
18. Tang, M.H., Ching, C.K., Tsui, M.S., Chu, F.K., Mak, T.W. (2014) Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clinical Toxicology (Philadelphia), 52, 561-565.
19. Laskowski, L.K., Elbakoush, F., Calvo, J., Exantus-Bernard, G., Fong, J., Poklis, J.L. et al. (2015) Evolution of the NBOMes: 25C- and 25B-sold as 25I-NBOMe. Journal of Medical Toxicology, 11, 237-241.
20. Johnson, R.D., Botch-Jones, S.R., Flowers, T., Lewis, C.A. (2014) An evaluation of 25B-, 25C-, 25D-, 25H-, 25I- and 25T2-NBOMe via LC-MS-MS: method validation and analyte stability. Journal of Analytical Toxicology, 38, 479-484.
21. Grautoff, S., Kähler, J. (2014) Near fatal intoxication with the novel psychoactive substance 25C-NBOMe. Medizinische Klinik -Intensivmedizin und Notfallmedizin, 109, 271-275.
22. Walterscheid, J.P., Phillips, G.T., Lopez, A.E., Gonsoulin, M.L., Chen, H.H., Sanchez, L.A. (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. The American Journal of Forensic Medicine and Pathology, 35, 20-25.
23. Poklis, J.L., Devers, K.G., Arbefeville, E.F., Julia, M., Pearson, J.M., Houston, E. et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Science International, 234, 14-20.
24. Drug Enforcement Administration. Department of Justice (2014) Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule, I. Final order. Drug Enforcement Administration. Department of Justice. Federal Register, 78, 716-719.
25. Forrester, M.B. (2014) NBOMe designer drug exposures reported to Texas poison centers. Journal of Addictive Diseases, 33, 196-201.
26. Nikolaou, P., Papoutsis, I., Stefanidou, M., Spiliopoulou, C., Athanaselis, S. (2015) 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects. Drug and Chemical Toxicology, 38, 113-119.
27. Lawn,W., Barratt, M.,Williams, M., Horne, A.,Winstock, A. (2014) The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. Journal of Psychopharmacology, 28, 780-788.
28. Suzuki, J., Dekker, M.A., Valenti, E.S., Arbelo Cruz, F.A., Correa, A.M., Poklis, J.L. et al. (2015) Toxicities associated with NBOMe ingestion, a novel class of potent hallucinogens: a review of the literature. Psychosomatics, 56, 129-139.
29. Steiner, R.R., Larson, R.L. (2009) Validation of the direct analysis in real time source for use in forensic drug screening. Journal of Forensic Science, 54, 617-622.
30. Poklis, J.L., Clay, D.J., Poklis, A. (2014) High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. Journal of Analytical Toxicology, 35, 113-121.